Arabic Arabic English English French French German German
dark

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“ Immutep ” or the “ Company ”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti” or “IMP321”), EOC Pharma (“EOC”) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Medtech Incubators and Accelerators: Where Are the Hubs for Medical Device Innovation?

Next Post

Organ transplants fell by a third worldwide during first wave of COVID-19 pandemic, new study presented at ESOT Congress 2021 shows

Related Posts
Total
0
Share